SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Suneva Medical, Inc., announced today that it has amended its existing licensing agreement with Histogen, Inc. Under the terms of the amended agreement, Suneva Medical is the exclusive licensee for the distribution of the Regenica® skincare line through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East. Suneva Medical remains the exclusive licensee in the physician-dispensed channel for Regenica in the United States.
Regenica contains Histogen's proprietary Multipotent Cell Conditioned Media with growth factors and stem-cell derived proteins that are characteristic of young, rapidly developing tissue and are associated with skin rejuvenation and repair. "Regenica's growing customer base is a testament to the product's ability to rejuvenate the skin, accelerating the body's own cells' ability to repair and renew," stated Nicholas L. Teti Jr., Chairman and Chief Executive Officer of Suneva Medical. "With this amended licensing agreement in place, international consumers will now have access to the latest U.S. growth factor technology."
"Regenica is unlike any product currently on the market in the U.S. or internationally. The unique formula triggers cells to naturally produce proteins associated with skin renewal and healing," commented Dr. Gail K. Naughton, Chief Executive Officer and Chairman of the Board at Histogen. "With the Suneva team at the helm, there is no doubt that Regenica is well-positioned to become an international success."
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets Artefill® in the US, Korea, Singapore, and Vietnam; Refissa® and Regenica® Skincare in the U.S.; and Bellafill® in Canada. For more information, visit www.sunevamedical.com.
Regenica® is a trademark of Suneva Medical, Inc. The Multipotent Cell Conditioned Media Complex is covered by U.S. patents #8,257,947 and #8,524,494.
SOURCE Suneva Medical, Inc.